Mental or Behavioral Dysfunction – Page 9

Neurocrine-Takeda Collaboration Shows Promise in Alleviating Depression Symptoms in Phase 2 Trials

1 year ago talkbio0Tagged Mental Depression, Neurocrine, Phase 2 Trials, Severities, Takeda

Neurocrine, Takeda, Phase 2 trials, depression, depression severity, medication, analysts, data detail.

Intra-Cellular’s Caplyta Triumphs in Major Depressive Disorder Phase 3 Trial, Edging Closer to FDA Filing

1 year ago talkbio0Tagged Caplyta, CGI-S, Clinical Global Impression Original Version Questionnaire, clinically, File (record), Intra-Cellular Therapies, Lumateperone, MADRS, MDD, Montgomery-Åsberg depression rating scale, Phase 3 trial, Positive, results, Severities, Statistical Significance, Unipolar Depression, United States Food and Drug Administration

Intra-Cellular Therapies, Caplyta, Lumateperone, Major Depressive Disorder (MDD), Phase 3 Trial, Positive Results, Statistically Significant, Clinically Meaningful, Montgomery-Åsberg Depression Rating Scale (MADRS), Clinical Global Impression Scale for Severity of Illness (CGI-S), FDA Filing

Intra-Cellular’s Caplyta Shows Promising Results in Major Depressive Disorder Study

1 year ago talkbio0Tagged adjunctive therapy, blockbuster label, Caplyta, Clinical Global Impression Original Version Questionnaire, expansion, Intra-Cellular Therapies, Lumateperone, Major Depressive Disorder, MDD, Montgomery-Åsberg depression rating scale, Montgomery-Asberg Depression Rating Scale Questionnaire, Positive Clinical Trial, Study 501, Unipolar Depression

Intra-Cellular Therapies, Caplyta (lumateperone), Major Depressive Disorder (MDD), Positive clinical trial results, Study 501, Montgomery-Åsberg Depression Rating Scale (MADRS), Clinical Global Impression Scale, Adjunctive therapy, Potential blockbuster label expansion

Neumora’s Schizophrenia Drug Study Halted by FDA Due to Preclinical Safety Signals

1 year ago talkbio0Tagged Neumora, NMRA-266, Old World rabbit, Phase I Clinical Trials, Preclinical safety signals, Schizophrenia, Seizures, Study on Hold

Neumora Therapeutics, Schizophrenia drug study, NMRA-266, Preclinical safety signals, Convulsions in rabbits, Clinical hold, Phase I trial

Neumora Therapeutics’ Schizophrenia Drug NMRA-266 Faces FDA Hold Over Convulsions in Rabbits

1 year ago talkbio0Tagged Neumora, NMRA-266, Schizophrenia, Seizures, United States Food and Drug Administration

Neumora, United States Food and Drug Administration, NMRA-266, Seizures, Schizophrenia

Record-Breaking 323 Medications in Active Shortage in US, ASHP Reports

1 year ago talkbio0Tagged Active shortages, Adderall, American Society of Health-System Pharmacists, Antineoplastic Agents, ASHP, Attention deficit hyperactivity disorder, Drug Enforcement Administration, Drug shortages, Drug supply chains, Generic sterile injectable medications, Policy, Recommendation, Record-high

Drug shortages, US, Record-high, American Society of Health-System Pharmacists (ASHP), 323 medications, Active shortages, Generic sterile injectable medications, Cancer chemotherapy drugs, ADHD medications, Adderall, Drug Enforcement Administration (DEA), Drug supply chains, Policy recommendations

US Drug Shortages Hit Record High Since 2001: ASHP Report

1 year ago talkbio0Tagged ASHP, Attention deficit hyperactivity disorder, Biden administration, Central Nervous System Stimulants, Chemotherapy Drugs Adminstered, controlled substance, Defense Production Act, DPA, Drug Enforcement Administration, Drug shortages, hormone agents, Hospitals, Incentives, intravenous fluids, Microbicides, Quality concerns, Record high, American Society of Health-System Pharmacists, shortage, Supply Chain Resilience, White House Council

Drug shortages, Record high, American Society of Health-System Pharmacists (ASHP), 323 drugs in shortage, Chemotherapy drugs, ADHD therapies, Central nervous system stimulants, Antimicrobials, Hormone agents, Intravenous fluids, Drug Enforcement Administration (DEA), Biden administration, White House Council on Supply Chain Resilience, Defense Production Act (DPA), Incentives for hospitals, Quality concerns, Controlled substances